MC
VC

MPM Capital

Cambridge, United Statesmpmcapital.com

This VC invests across various stages and sectors. Discover their investment history, portfolio performance, and team members. Compare MPM Capital with similar firms and track their investment activity.

35
Investments Tracked

About MPM Capital

MPM Capital is a venture capital firm headquartered in Cambridge, the United States. We have recorded 35 investments for MPM Capital to date.

Sector activity concentrates in Healthcare & Life Sciences; Software & Developer Tools; Consumer, Lifestyle & Services and Oncology. Coverage extends to 8 sectors in total. Participation spans Series A, Series B and Series C+ rounds.

MPM Capital is a healthcare venture capital firm that invests in early-stage therapeutics companies. They focus on translating scientific innovations into cures for major diseases.

Investment Focus

Stage Focus
series-aseries-bseries-c-plus
Sectors
Healthcare & Life SciencesSoftware & Developer ToolsConsumer, Lifestyle & Servicesoncologypharmaceutical-developmentbiotechnologyGenomics & Molecular Biologyimmunotherapy

Investment Thesis

MPM Capital is a healthcare venture capital firm that invests in early-stage therapeutics companies. They focus on translating scientific innovations into cures for major diseases.

MPM Capital Portfolio Companies

24 of 40 tracked holdings.

Portfolio outcomes
23 active2 acquired6.1% exit rate

Team

Ansbert GadickeChairman

Chairman at MPM BioImpact; involved in building Orna Therapeutics and supporting Reunion Neuroscience.

Joseph BolenChief Executive Officer

Chief Executive Officer at Orna Therapeutics.

Frank NeumannChief Medical Officer

Chief Medical Officer at Orna Therapeutics; Entrepreneur Partner at MPM BioImpact.

Matthew RodenChief Executive Officer

Chief Executive Officer at Aktis Oncology; Entrepreneur Partner at MPM BioImpact.

Todd FoleyChairman

Chairman at Aktis Oncology; Investment Team member at MPM BioImpact.

Michael EhlersBoard Member

Board Member involved with Reunion Neuroscience; commented on positive Phase 2 trial results.

Chris BardonManaging Partner

Managing Partner at MPM BioImpact; early public investor in argenx.

Briggs MorrisonEntrepreneur Partner

Entrepreneur Partner at MPM BioImpact.

Aparna ParikhEntrepreneur Partner

Entrepreneur Partner at MPM BioImpact.

Andrew ScharenbergEntrepreneur Partner

Entrepreneur Partner at MPM BioImpact.

Rami RahalPartner

Investment Team member promoted to Partner at MPM BioImpact in January 2025.

Detlev BiniszkiewiczInvestment Team

Investment Team member at MPM BioImpact.

Explore MPM Capital's full profile on Brouky

Portfolio companies, co-investors, AI match scores, and deal flow signals.

Other Investors in United States

Other Investors in Healthcare & Life Sciences / Software & Developer Tools